Quibiotic SAS

#HealthTech #Innovative therapies

• Innovation
• Synthesis
• Platforms
• Beta-lactam ring
• Anti-infectives

BACKGROUND
The roots of Quibiotic’s technology are to be found in an initial independent patent filed in 2016 by Paolo Bonomi. The base concept of the Quibiotic project is to reconsider lactam rings with the goal of developing novel therapeutics. In 2018, a second Italian patent was filed, in 2019, the project was selected for the Genopole Shaker program and in 2020 a third patent was filed. Thereafter, Quibiotic was officially created on 10 October 2021 by four associates with complementary competencies.

DESCRIPTION OF THE PRODUCTS / SERVICES / TECHNOLOGY
Quibiotic proposes three molecular synthesis platforms for the chemical modification of β-lactam rings in only three to four steps. The company’s technology makes it possible to link any given biologically active molecule to the β-lactam ring. Experimental trials have demonstrated class D β-lactamase inhibition activity for a first molecule and antineoplastic activity for a second one.

ACCOMPLISHMENTS / PARTNERSHIPS / HIGHLIGHTS
A project is currently underway in partnership with the University of Évry-Paris Saclay and Professor N. Jarroux at Lambe to study the complexation of different substrates with cyclodextrins. The goal of this work is to modulate the bioavailability or the activity of our novel compounds.
PARTNERSHIPS SOUGHT
We are actively seeking project partnerships with public and/or private institutions to empower the development of our platforms and to enable symbiotic relations with other technologies complementary to ours.

• Further information

  3 patents

  Strengths
  Innovation in molecular synthesis strategies. Creation of a library of novel compounds. Simple chemical steps. Expertise in chemistry & biology + complementary competencies among the associates and an advisory board.

  Innovation assets
  A new way of thinking about β-lactam matrices.

  Other facts
  Passion, dedication and ethics.